Tuberculosis and pharmacological interactions: A narrative review



Even if major improvements in therapeutic regimens and treatment outcomes have been progressively achieved,
tuberculosis (TB) remains the leading cause of death from a single infectious microorganism. To improve TB
treatment success as well as patients’ quality of life, drug-drug-interactions (DDIs) need to be wisely managed.

Comprehensive knowledge of anti-TB drugs, pharmacokinetics and pharmacodynamic (PK/PD) parameters, po-
tential patients’ changes in absorption and distribution, possible side effects and interactions, is mandatory to

built effective anti-TB regimens. Optimization of treatments and adherence to international guidelines can help
bend the curve of TB-related mortality and, ultimately, decrease the likelihood of treatment failure and drop-out
during anti-TB treatment. Aim of this paper is to describe the most relevant DDIs between anti-TB and other drugs

used in daily clinical practice, providing an updated and “easy-to-use” guide to minimize adverse effects, drop-
outs and, in the long run, increase treatment success.

Niccolo Riccardi, Diana Canetti, Paola Rodari, Giorgio Besozzi, Laura Saderi, Marco Dettori, Luigi R. Codecasa, Giovanni Sotgiu.


Continua a leggere: Studio Scientifico completo

- Tag: , , ,



accetto la privacy